PDE4 inhibitors: potential protective effects in inflammation and vascular diseases

T Fan, W Wang, Y Wang, M Zeng, Y Liu… - Frontiers in …, 2024‏ - frontiersin.org
Phosphodiesterase 4 (PDE4) inhibitors are effective therapeutic agents for various
inflammatory diseases. Roflumilast, apremilast, and crisaborole have been developed and …

[HTML][HTML] Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system

Z Donders, IJ Skorupska, E Willems, F Mussen… - Biomedicine & …, 2024‏ - Elsevier
Cyclic adenosine monophosphate (cAMP) is a key second messenger that regulates signal
transduction pathways pivotal for numerous biological functions. Intracellular cAMP levels …

Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-β pathology

D Paes, M Schepers, E Willems, B Rombaut… - Cellular and Molecular …, 2023‏ - Springer
Inhibition of phosphodiesterase 4D (PDE4D) enzymes has been investigated as therapeutic
strategy to treat memory problems in Alzheimer's disease (AD). Although PDE4D inhibitors …

Meningeal lymphatic function promotes oligodendrocyte survival and brain myelination

SP das Neves, N Delivanoglou, Y Ren, CS Cucuzza… - Immunity, 2024‏ - cell.com
The precise neurophysiological changes prompted by meningeal lymphatic dysfunction
remain unclear. Here, we showed that inducing meningeal lymphatic vessel ablation in adult …

[HTML][HTML] PDE4D: a multipurpose pharmacological target

M Lusardi, F Rapetti, A Spallarossa… - International Journal of …, 2024‏ - mdpi.com
Phosphodiesterase 4 (PDE4) enzymes catalyze cyclic adenosine monophosphate (cAMP)
hydrolysis and are involved in a variety of physiological processes, including brain function …

Hypoxic oligodendrocyte precursor cell-derived VEGFA is associated with blood–brain barrier impairment

N Manukjan, D Majcher, P Leenders, F Caiment… - Acta neuropathologica …, 2023‏ - Springer
Cerebral small vessel disease is characterised by decreased cerebral blood flow and blood–
brain barrier impairments which play a key role in the development of white matter lesions …

Induced pluripotent stem cells and organoids in advancing neuropathology research and therapies

DB Pazzin, TTR Previato, JI Budelon Gonçalves… - Cells, 2024‏ - mdpi.com
This review delves into the groundbreaking impact of induced pluripotent stem cells (iPSCs)
and three-dimensional organoid models in propelling forward neuropathology research …

Unleashing spinal cord repair: the role of cAMP-specific PDE inhibition in attenuating neuroinflammation and boosting regeneration after traumatic spinal cord injury

F Mussen, JV Broeckhoven, N Hellings… - International journal of …, 2023‏ - mdpi.com
Traumatic spinal cord injury (SCI) is characterized by severe neuroinflammation and
hampered neuroregeneration, which often leads to permanent neurological deficits. Current …

Short PDE4 isoforms as drug targets in disease

E Kyurkchieva, GS Baillie - Frontiers in Bioscience: Landmark, 2023‏ - eprints.gla.ac.uk
The second messenger, cyclic adenosine monophosphate (cAMP), is a master regulator of
signal transduction that maintains cell homeostasis. A fine balance between cAMP synthesis …

[HTML][HTML] Roflumilast and cognition enhancement: A translational perspective

J Prickaerts, J Kerckhoffs, N Possemis… - Biomedicine & …, 2024‏ - Elsevier
Cognitive impairment affiliated with neurological disorders has a severe impact on daily life
functioning and the quality of life of patients. This is associated with a significant and long …